Eris Lifesciences Limited (NSE:ERIS)
1,354.00
-21.20 (-1.54%)
Jul 31, 2026, 3:30 PM IST
Eris Lifesciences Revenue
Eris Lifesciences had revenue of 8.69B INR in the quarter ending June 30, 2026, with 12.63% growth. This brings the company's revenue in the last twelve months to 32.12B, up 9.44% year-over-year. In the fiscal year ending March 31, 2026, Eris Lifesciences had annual revenue of 31.15B with 8.18% growth.
Revenue (ttm)
32.12B
Revenue Growth
+9.44%
P/S Ratio
5.84
Revenue / Employee
9.58M
Employees
3,354
Market Cap
187.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 31.15B | 2.36B | 8.18% |
| Mar 31, 2025 | 28.79B | 8.88B | 44.59% |
| Mar 31, 2024 | 19.91B | 3.29B | 19.83% |
| Mar 31, 2023 | 16.62B | 3.36B | 25.31% |
| Mar 31, 2022 | 13.26B | 1.34B | 11.20% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Piramal Pharma | 92.05B |
| Emcure Pharmaceuticals | 92.04B |
| Alembic Pharmaceuticals | 73.45B |
| Gland Pharma | 64.31B |
| Strides Pharma Science | 48.59B |
| Akums Drugs and Pharmaceuticals | 43.61B |
| NATCO Pharma | 40.78B |
| Wockhardt | 34.62B |
Eris Lifesciences News
- 3 days ago - Eris Lifesciences Transcript: Q1 26/27 - Transcripts
- 3 days ago - Eris Lifesciences Slides: Q1 2027 - Filings
- 3 days ago - Eris Lifesciences Quarterly report: Q1 2027 - Filings
- 5 weeks ago - Eris Lifesciences Slides: Corporate presentation - Filings
- 5 weeks ago - Eris Lifesciences achieves top-5 market position in anti-diabetes therapy - Business Upturn
- 7 weeks ago - Eris Lifesciences pays Rs 54.56 crore interest on outstanding debentures - Business Upturn
- 2 months ago - Eris Lifesciences Transcript: Q4 25/26 - Transcripts
- 2 months ago - Eris Lifesciences Slides: Q4 2026 - Filings